Guojin Securities: First gives Ahead Pharmaceutical (02096.HK) a "buy" rating with a target price of HK$20.16.

According to the Zhixun Financial APP, Guojin Securities released a research report stating that Sinopharm Holdings (02096.HK) has a strong growth certainty with short-term pipeline volume and long-term innovation iteration forming resonance. It is forecasted that the company will achieve operating income of 7.63 billion/9.10 billion/11.04 billion yuan in 2025/2026/2027, with year-on-year growth of +15.0%/+19.3%/+21.4%, and a net profit attributable to shareholders of 1.15 billion/1.38 billion/1.66 billion yuan, with year-on-year growth of +57.3%/+19.4%/+20.5%, corresponding to an EPS of 0.44/0.53/0.64 yuan (taking into account the 1.12 billion new shares issued in September 2025). According to the DCF valuation, the corresponding fair target price is 20.16 Hong Kong dollars. This is the first coverage report, with a "buy" rating.